Accro Bioscience Raises $50 Million In Series C Funding Led By OrbiMed And TCG Crossover

Accro Bioscience Inc., a Suzhou-based clinical-stage biotechnology company, raised $50 million in Series C funding to advance its Phase IIb clinical trial of AC-101, a RIPK2 inhibitor for ulcerative colitis, and to develop additional immunology and inflammation pipeline candidates.

Summary of transaction details:

• Deal Type: Series C
• Transaction Amount: $50,000,000
• Company Headquarters: Suzhou Industrial Park, Jiangsu, China
• Notable Investors: OrbiMed, TCG Crossover, LAV, Cenova Capital, Shenzhen Capital Group, Oriza Holdings

Accro Bioscience is led by CEO Dr. Xiaohu (Jason) Zhang, focusing on therapeutics that target molecular mechanisms of regulatory cell death. The company is actively engaged in addressing inflammatory and autoimmune diseases through its innovative research initiatives.